Drug intelligence / Profile preview

RMD-003

Development stage: Preclinical
Lead developer: Remedium Bio
Modality: Gene Therapies, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Injection

Overview

RMD-003 is an adjustable gene therapy candidate being developed by Remedium Technologies for the treatment of obesity, type 2 diabetes, and sarcopenia. It utilizes the company's proprietary Prometheus™ platform, which is designed to allow for dose-adjustable expression of therapeutic transgenes, addressing the historical limitation of fixed-dose gene therapies. The candidate is engineered for delivery using either adeno-associated virus (AAV) or lipid nanoparticle (LNP) vectors. RMD-003 is part of the RMD1xx series, which focuses on metabolic and endocrinology indications. As of early 2024, the program is in the discovery stage of development.

Beyond the preview

Go deeper on RMD-003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RMD-003.

Explore the full profile